Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.16 is 125% above its 1-year average of -0.67, near the high end of its 1-year range (-1.91–0.16).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.16.
DEBT TO EQUITY RATIO
0.16
DEBT TO EQUITY RATIO AVG TTM
N/A
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 589 covered companies
CURRENT VS SECTOR MEDIAN
+26.39%
vs the sector median at left
Alamar Biosciences, Inc.
Market Cap
$2.44B
Debt to Equity Ratio
0.16
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.45B
Debt to Equity Ratio
0.09
TTM Avg
0.04
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$2.41B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$2.41B
Debt to Equity Ratio
0.07
TTM Avg
0.09
3Y Avg
0.10
5Y Avg
0.08
Market Cap
$2.39B
Debt to Equity Ratio
0.50
TTM Avg
0.21
3Y Avg
0.62
5Y Avg
0.72
Market Cap
$2.38B
Debt to Equity Ratio
0.66
TTM Avg
3.00
3Y Avg
1.83
5Y Avg
1.30
Market Cap
$2.37B
Debt to Equity Ratio
0.14
TTM Avg
0.08
3Y Avg
0.08
5Y Avg
0.06
Market Cap
$2.31B
Debt to Equity Ratio
0.15
TTM Avg
0.28
3Y Avg
0.36
5Y Avg
0.75
Market Cap
$2.30B
Debt to Equity Ratio
0.86
TTM Avg
0.66
3Y Avg
0.97
5Y Avg
2.06
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.44B | 0.16 | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.45B | 0.09 | 0.04 | 0.02 | 0.02 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 0.00 | 0.00 | 0.01 | 0.02 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | 0.07 | 0.09 | 0.10 | 0.08 |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 0.50 | 0.21 | 0.62 | 0.72 |
| Liquidia Corporation (LQDA)vs › | $2.38B | 0.66 | 3.00 | 1.83 | 1.30 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | 0.14 | 0.08 | 0.08 | 0.06 |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 0.15 | 0.28 | 0.36 | 0.75 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | 0.86 | 0.66 | 0.97 | 2.06 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.62B | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.16
Current Ratio
11.85
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.16 |
| 2026-03-31 | -1.91 |
| 2025-12-31 | -0.26 |
